nach oben

Strahlentherapie und Onkologie

Erschienen in:

12.09.2018 | Original Article

MRI-guided localization of the dominant intraprostatic lesion and dose analysis of volumetric modulated arc therapy planning for prostate cancer

verfasst von: Dr. med. Jörg Tamihardja, Maria Zenk, Michael Flentje

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Primary radiation therapy is a curative treatment option for prostate cancer. The aim of this study was to evaluate the detection of the dominant intraprostatic lesion (DIL) with magnetic resonance imaging (MRI) for radiotherapy treatment planning, the comparison with transrectal ultrasound (TRUS)-guided biopsies and the examination of the dose distribution in relation to the DIL location.

Materials and methods

In all, 54 patients with treatment planning MRI for primary radiotherapy of prostate cancer from 03/2015 to 03/2017 at the Universitätsklinikum Würzburg were identified. The localization of the DIL was based on MRI with T2- and diffusion-weighted imaging. After registration of the MR image sets within Pinnacle³ (Philips Radiation Oncology Systems, Fitchburg, WI, USA), the dose distribution was analyzed. The location of the DIL was compared to the pathology reports in a side-based manner.

Results

The DIL mean dose (Dmean) was 77.51 ± 0.77 Gy and in 50/51 cases within the tolerance range or exceeded the prescribed dose. There was a significant difference in Dmean between ventral (n = 21) and dorsal (n = 30) DIL (77.87 ± 0.67 vs. 77.26 ± 0.77 Gy; p = 0.005). MRI-guided localization showed an accuracy and sensitivity of up to 78.8% and 82.1% for inclusion of secondary lesions, respectively.

Conclusion

Up to 82.1% of histologically verified intraprostatic lesions were identified in the context of MRI-guided radiotherapy treatment planning. As expected, dorsal DIL tend to be minimally underdosed in comparison to ventral DIL. Adequate dose coverage was achieved in over 98% of patients.

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F (2013) Dosimetric implications of inter- and intrafractional prostate positioning errors during tomotherapy: comparison of gold marker-based registrations with native MVCT. Eur J Cancer 49(6):1374–1403. https://doi.org/10.1016/j.ejca.2012.12.027 CrossRefPubMed

Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM, Oxley J, Robinson M, Staffurth J, Walsh E, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Paul A, Powell P, Prescott S, Rosario DJ, Rowe E, Neal DE (2016) 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375(15):1415–1424. https://doi.org/10.1056/NEJMoa1606220 CrossRefPubMed

Kishan AU, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Sandler KA, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Stephenson AJ, Klein EA, Song DY, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D’Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco S, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR (2018) Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with Brachytherapy boost and disease progression and mortality in patients with Gleason score 9–10 prostate cancer. JAMA 319(9):896–905. https://doi.org/10.1001/jama.2018.0587 CrossRefPubMedPubMedCentral

Delobel JB, Gnep K, Ospina JD, Beckendorf V, Chira C, Zhu J, Bossi A, Messai T, Acosta O, Castelli J, de Crevoisier R (2017) Nomogram to predict rectal toxicity following prostate cancer radiotherapy. PLoS ONE 12(6):e179845. https://doi.org/10.1371/journal.pone.0179845 CrossRefPubMedPubMedCentral

Guckenberger M, Lawrenz I, Flentje M (2014) Moderately hypofractionated radiotherapy for localized prostate cancer: long-term outcome using IMRT and volumetric IGRT. Strahlenther Onkol 190(1):48–53. https://doi.org/10.1007/s00066-013-0443-x CrossRefPubMed

Ahmed HU (2009) The index lesion and the origin of prostate cancer. N Engl J Med 361(17):1704–1706. https://doi.org/10.1056/NEJMcibr0905562 CrossRefPubMed

Wise AM, Stamey TA, McNeal JE, Clayton JL (2002) Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 60(2):264–269CrossRef

Noguchi M, Stamey TA, McNeal JE, Nolley R (2003) Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers. J Urol 170(2 Pt 1):459–463. https://doi.org/10.1097/01.ju.0000070928.49986.04 CrossRefPubMed

Pucar D, Hricak H, Shukla-Dave A, Kuroiwa K, Drobnjak M, Eastham J, Scardino PT, Zelefsky MJ (2007) Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys 69(1):62–69. https://doi.org/10.1016/j.ijrobp.2007.03.065 CrossRefPubMed

10.

Cellini N, Morganti AG, Mattiucci GC, Valentini V, Leone M, Luzi S, Manfredi R, Dinapoli N, Digesu C, Smaniotto D (2002) Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys 53(3):595–599CrossRef

11.

Karavitakis M, Winkler M, Abel P, Livni N, Beckley I, Ahmed HU (2011) Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: implications for focal therapy. Prostate Cancer Prostatic Dis 14(1):46–52. https://doi.org/10.1038/pcan.2010.16 CrossRefPubMed

12.

van der Poel HG, van den Bergh RCN, Briers E, Cornford P, Govorov A, Henry AM, Lam TB, Mason MD, Rouviere O, De Santis M, Willemse PM, van Poppel H, Mottet N (2018) Focal therapy in primary localised prostate cancer: the European Association of Urology position in 2018. Eur Urol. https://doi.org/10.1016/j.eururo.2018.01.001 CrossRefPubMed

13.

Peach MS, Trifiletti DM, Libby B (2016) Systematic review of focal prostate brachytherapy and the future implementation of image-guided prostate HDR brachytherapy using MR-ultrasound fusion. Prostate Cancer. https://doi.org/10.1155/2016/4754031 CrossRefPubMedPubMedCentral

14.

Monninkhof EM, van Loon JWL, van Vulpen M, Kerkmeijer LGW, Pos FJ, Haustermans K, van den Bergh L, Isebaert S, McColl GM, Smeenk JR, Noteboom J, Walraven I, Peeters PHM, van der Heide UA (2018) Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: toxicity in the FLAME randomized controlled trial. Radiother Oncol. https://doi.org/10.1016/j.radonc.2017.12.022 CrossRefPubMed

15.

von Eyben FE, Kiljunen T, Kangasmaki A, Kairemo K, von Eyben R, Joensuu T (2016) Radiotherapy boost for the dominant intraprostatic cancer lesion-a systematic review and meta-analysis. Clin Genitourin Cancer 14(3):189–197. https://doi.org/10.1016/j.clgc.2015.12.005 CrossRef

16.

Sundahl N, De Meerleer G, Villeirs G, Ost P, De Neve W, Lumen N, De Visschere P, Van Eijkeren M, Fonteyne V (2016) Combining high dose external beam radiotherapy with a simultaneous integrated boost to the dominant intraprostatic lesion: analysis of genito-urinary and rectal toxicity. Radiother Oncol 119(3):398–404. https://doi.org/10.1016/j.radonc.2016.04.031 CrossRefPubMed

17.

Timon G, Ciardo D, Bazani A, Garioni M, Maestri D, De Lorenzo D, Pansini F, Cambria R, Rondi E, Cattani F, Marvaso G, Zerini D, Vischioni B, Ciocca M, Russo S, Molinelli S, Golino F, Scroffi V, Rojas DP, Fodor C, Petralia G, Santoro L, De Cobelli O, Orecchia R, Jereczek-Fossa BA (2016) Rationale and protocol of AIRC IG-13218, short-term radiotherapy for early prostate cancer with concomitant boost to the dominant lesion. Tumori 102(5):536–540. https://doi.org/10.5301/tj.5000547 CrossRefPubMed

18.

Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, Margolis D, Schnall MD, Shtern F, Tempany CM, Thoeny HC, Verma S (2016) PI-RADS prostate imaging—reporting and data system: 2015, version 2. Eur Urol 69(1):16–40. https://doi.org/10.1016/j.eururo.2015.08.052 CrossRefPubMed

19.

Oberlin DT, Casalino DD, Miller FH, Meeks JJ (2017) Dramatic increase in the utilization of multiparametric magnetic resonance imaging for detection and management of prostate cancer. Abdom Radiol (NY) 42(4):1255–1258. https://doi.org/10.1007/s00261-016-0975-5 CrossRef

20.

McPartlin AJ, Li XA, Kershaw LE, Heide U, Kerkmeijer L, Lawton C, Mahmood U, Pos F, van As N, van Herk M, Vesprini D, van der Voort van Zyp J, Tree A, Choudhury A (2016) MRI-guided prostate adaptive radiotherapy—a systematic review. Radiother Oncol 119(3):371–380. https://doi.org/10.1016/j.radonc.2016.04.014 CrossRefPubMed

21.

Combs SE, Nusslin F, Wilkens JJ (2016) Individualized radiotherapy by combining high-end irradiation and magnetic resonance imaging. Strahlenther Onkol 192(4):209–215. https://doi.org/10.1007/s00066-016-0944-5 CrossRefPubMed

22.

Bostel T, Pfaffenberger A, Delorme S, Dreher C, Echner G, Haering P, Lang C, Splinter M, Laun F, Muller M, Jakel O, Debus J, Huber PE, Sterzing F, Nicolay NH (2018) Prospective feasibility analysis of a novel off-line approach for MR-guided radiotherapy. Strahlenther Onkol 194(5):425–434. https://doi.org/10.1007/s00066-017-1258-y CrossRefPubMed

23.

Lips IM, van der Heide UA, Haustermans K, van Lin EN, Pos F, Franken SP, Kotte AN, van Gils CH, van Vulpen M (2011) Single blind randomized phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): study protocol for a randomized controlled trial. Trials 12:255. https://doi.org/10.1186/1745-6215-12-255 CrossRefPubMedPubMedCentral

24.

Isebaert S, Van den Bergh L, Haustermans K, Joniau S, Lerut E, De Wever L, De Keyzer F, Budiharto T, Slagmolen P, Van Poppel H, Oyen R (2013) Multiparametric MRI for prostate cancer localization in correlation to whole-mount histopathology. J Magn Reson Imaging 37(6):1392–1401. https://doi.org/10.1002/jmri.23938 CrossRefPubMed

25.

Chabanova E, Balslev I, Logager V, Hansen A, Jakobsen H, Kromann-Andersen B, Norgaard N, Horn T, Thomsen HS (2011) Prostate cancer: 1.5 T endo-coil dynamic contrast-enhanced MRI and MR spectroscopy—correlation with prostate biopsy and prostatectomy histopathological data. Eur J Radiol 80(2):292–296. https://doi.org/10.1016/j.ejrad.2010.07.004 CrossRefPubMed

26.

Rud E, Klotz D, Rennesund K, Baco E, Berge V, Lien D, Svindland A, Lundeby E, Berg RE, Eri LM, Eggesbo HB (2014) Detection of the index tumour and tumour volume in prostate cancer using T2-weighted and diffusion-weighted magnetic resonance imaging (MRI) alone. BJU Int 114(6b):E32–E42. https://doi.org/10.1111/bju.12637 CrossRefPubMed

27.

Seisen T, Roudot-Thoraval F, Bosset PO, Beaugerie A, Allory Y, Vordos D, Abbou CC, De La Taille A, Salomon L (2015) Predicting the risk of harboring high-grade disease for patients diagnosed with prostate cancer scored as Gleason ≤6 on biopsy cores. World J Urol 33(6):787–792. https://doi.org/10.1007/s00345-014-1348-8 CrossRefPubMed

28.

Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, Collaco-Moraes Y, Ward K, Hindley RG, Freeman A, Kirkham AP, Oldroyd R, Parker C, Emberton M (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389(10071):815–822. https://doi.org/10.1016/s0140-6736(16)32401-1 CrossRefPubMed

29.

Pokorny MR, de Rooij M, Duncan E, Schroder FH, Parkinson R, Barentsz JO, Thompson LC (2014) Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol 66(1):22–29. https://doi.org/10.1016/j.eururo.2014.03.002 CrossRefPubMed

30.

Pal RP, Ahmad R, Trecartan S, Voss J, Ahmed S, Bazo A, Lloyd J, Walton TJ (2018) A single-centre evaluation of the diagnostic accuracy of multiparametric MRI against transperineal prostate mapping biopsy: an analysis of men with bengin histology and insignificant cancer following TRUS biopsy. J Urol. https://doi.org/10.1016/j.juro.2018.02.072 CrossRefPubMed

31.

Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budaus L, Hellawell G, Hindley RG, Roobol MJ, Eggener S, Ghei M, Villers A, Bladou F, Villeirs GM, Virdi J, Boxler S, Robert G, Singh PB, Venderink W, Hadaschik BA, Ruffion A, Hu JC, Margolis D, Crouzet S, Klotz L, Taneja SS, Pinto P, Gill I, Allen C, Giganti F, Freeman A, Morris S, Punwani S, Williams NR, Brew-Graves C, Deeks J, Takwoingi Y, Emberton M, Moore CM (2018) MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. https://doi.org/10.1056/NEJMoa1801993 CrossRefPubMed

32.

Park H, Piert MR, Khan A, Shah R, Hussain H, Siddiqui J, Chenevert TL, Meyer CR (2008) Registration methodology for histological sections and in vivo imaging of human prostate. Acad Radiol 15(8):1027–1039. https://doi.org/10.1016/j.acra.2008.01.022 CrossRefPubMedPubMedCentral

33.

Greer MD, Shih JH, Barrett T, Bednarova S, Kabakus I, Law YM, Shebel H, Merino MJ, Wood BJ, Pinto PA, Choyke PL, Turkbey B (2018) All over the map: an interobserver agreement study of tumor location based on the PI-RADSv2 sector map. J Magn Reson Imaging. https://doi.org/10.1002/jmri.25948 CrossRefPubMed

34.

Shiradkar R, Podder TK, Algohary A, Viswanath S, Ellis RJ, Madabhushi A (2016) Radiomics based targeted radiotherapy planning (Rad-TRaP): a computational framework for prostate cancer treatment planning with MRI. Radiat Oncol 11(1):148. https://doi.org/10.1186/s13014-016-0718-3 CrossRefPubMedPubMedCentral

35.

Parra NA, Pollack A, Chinea FM, Abramowitz MC, Marples B, Munera F, Castillo R, Kryvenko ON, Punnen S, Stoyanova R (2017) Automatic detection and quantitative DCE-MRI scoring of prostate cancer aggressiveness. Front Oncol 7:259. https://doi.org/10.3389/fonc.2017.00259 CrossRefPubMedPubMedCentral

36.

Peeken JC, Nusslin F, Combs SE (2017) “Radio-oncomics”: the potential of radiomics in radiation oncology. Strahlenther Onkol 193(10):767–779. https://doi.org/10.1007/s00066-017-1175-0 CrossRefPubMed

37.

Ciardo D, Jereczek-Fossa BA, Petralia G, Timon G, Zerini D, Cambria R, Rondi E, Cattani F, Bazani A, Ricotti R, Garioni M, Maestri D, Marvaso G, Romanelli P, Riboldi M, Baroni G, Orecchia R (2017) Multimodal image registration for the identification of dominant intraprostatic lesion in high-precision radiotherapy treatments. Br J Radiol 90(1079):20170021. https://doi.org/10.1259/bjr.20170021 CrossRefPubMedPubMedCentral

38.

Harvey H, Orton MR, Morgan VA, Parker C, Dearnaley D, Fisher C, deSouza NM (2017) Volumetry of the dominant intraprostatic tumour lesion: intersequence and interobserver differences on multiparametric MRI. Br J Radiol 90(1071):20160416. https://doi.org/10.1259/bjr.20160416 CrossRefPubMedPubMedCentral

39.

Steenbergen P, Haustermans K, Lerut E, Oyen R, De Wever L, Van den Bergh L, Kerkmeijer LG, Pameijer FA, Veldhuis WB, van der Voort van Zyp JR, Pos FJ, Heijmink SW, Kalisvaart R, Teertstra HJ, Dinh CV, Ghobadi G, van der Heide UA (2015) Prostate tumor delineation using multiparametric magnetic resonance imaging: inter-observer variability and pathology validation. Radiother Oncol 115(2):186–190. https://doi.org/10.1016/j.radonc.2015.04.012 CrossRefPubMed

40.

Chen Z, Zheng Y, Ji G, Liu X, Li P, Cai L, Guo Y, Yang J (2017) Accuracy of dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate cancer: systematic review and meta-analysis. Oncotarget 8(44):77975–77989. https://doi.org/10.18632/oncotarget.20316 CrossRefPubMedPubMedCentral

41.

Woo S, Suh CH, Kim SY, Cho JY, Kim SH (2018) Head-to-head comparison between high- and standard-b-value DWI for detecting prostate cancer: a systematic review and meta-analysis. AJR Am J Roentgenol 210(1):91–100. https://doi.org/10.2214/ajr.17.18480 CrossRefPubMed

42.

Boda-Heggemann J, Kohler FM, Wertz H, Ehmann M, Hermann B, Riesenacker N, Kupper B, Lohr F, Wenz F (2008) Intrafraction motion of the prostate during an IMRT session: a fiducial-based 3D measurement with Cone-beam CT. Radiat Oncol 3:37. https://doi.org/10.1186/1748-717x-3-37 CrossRefPubMedPubMedCentral

43.

Badakhshi H, Wust P, Budach V, Graf R (2013) Image-guided radiotherapy with implanted markers and kilovoltage imaging and 6‑dimensional position corrections for intrafractional motion of the prostate. Anticancer Res 33(9):4117–4121PubMed

44.

Wilbert J, Baier K, Hermann C, Flentje M, Guckenberger M (2013) Accuracy of real-time couch tracking during 3‑dimensional conformal radiation therapy, intensity modulated radiation therapy, and volumetric modulated arc therapy for prostate cancer. Int J Radiat Oncol Biol Phys 85(1):237–242. https://doi.org/10.1016/j.ijrobp.2012.01.095 CrossRefPubMed

45.

Haekal M, Arimura H, Hirose TA, Shibayama Y, Ohga S, Fukunaga J, Umezu Y, Honda H, Sasaki T (2018) Computational analysis of interfractional anisotropic shape variations of the rectum in prostate cancer radiation therapy. Phys Med 46:168–179. https://doi.org/10.1016/j.ejmp.2017.12.019 CrossRefPubMed

46.

Shibayama Y, Arimura H, Hirose TA, Nakamoto T, Sasaki T, Ohga S, Matsushita N, Umezu Y, Nakamura Y, Honda H (2017) Investigation of interfractional shape variations based on statistical point distribution model for prostate cancer radiation therapy. Med Phys 44(5):1837–1845. https://doi.org/10.1002/mp.12217 CrossRefPubMed

47.

Wust P, Joswig M, Graf R, Bohmer D, Beck M, Barelkowski T, Budach V, Ghadjar P (2017) Dosimetric implications of inter- and intrafractional prostate positioning errors during tomotherapy: comparison of gold marker-based registrations with native MVCT. Strahlenther Onkol 193(9):700–706. https://doi.org/10.1007/s00066-017-1141-x CrossRefPubMed

Titel: MRI-guided localization of the dominant intraprostatic lesion and dose analysis of volumetric modulated arc therapy planning for prostate cancer
verfasst von: Dr. med. Jörg Tamihardja
Maria Zenk
Michael Flentje
Publikationsdatum: 12.09.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 2/2019
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-018-1364-5

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

MRI-guided localization of the dominant intraprostatic lesion and dose analysis of volumetric modulated arc therapy planning for prostate cancer

Abstract

Purpose

Materials and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

Genetische Risikofaktoren für ein Zweitmalignom bei Kindern nach einer ersten onkologischen Erkrankung

Phase II study of accelerated Linac-based SBRT in five consecutive fractions for localized prostate cancer

Penile bulb sparing in prostate cancer radiotherapy

Stereotaktische Strahlentherapie übertrifft Sorafenib beim fortgeschrittenen hepatozellulären Karzinom im Hinblick auf das Überleben

Efficacy of stereotactic body radiotherapy for unresectable or recurrent cholangiocarcinoma: a meta-analysis and systematic review

Towards a universal MRI atlas of the prostate and prostate zones

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie